FULL GUIDE TO FGFR3 INHIBS

[FoidBrutalizer]

FGFR3 Inhibitors & Height Growth
What is FGFR3?
FGFR3 (Fibroblast Growth Factor Receptor 3) acts partly like a brake on bone growth.

In conditions such as achondroplasia, an overactive FGFR3 signal tells growth-plate cartilage cells to grow and mature less than they normally would. This reduces the lengthening of the long bones.
N
Nature
+1

The idea behind an FGFR3 inhibitor:
Reduce the excessive FGFR3 signal
Allow growth-plate cells to function more normally
Increase the rate at which bones lengthen
Potentially increase eventual height while the growth plates are still open

1. INFIGRATINIB
Current evidence: Strongest of the four
Type: Oral FGFR1–3 tyrosine-kinase inhibitor
Development for growth: Specifically being studied in children with achondroplasia
Human height data: YES — Phase 3

This is currently the only drug on your list with large, placebo-controlled Phase 3 evidence specifically showing increased growth in children with achondroplasia.
N
New England Journal of Medicine

How much did it increase growth?
In the 2026 Phase 3 PROPEL 3 study:

114 children were randomized.
Children were 3–17 years old with open growth plates.
Treatment lasted 52 weeks.
The adjusted difference in annualized height velocity was +1.74 cm/year compared with placebo.
The observed mean difference was approximately +2.10 cm/year.
Height Z-score also improved.
There was also evidence of improved body proportionality in younger children.
N
New England Journal of Medicine
+1
What does +1.74 cm/year mean?
It doesn't mean the child will automatically become 1.74 cm taller overall.

It means that, during that year, their rate of height growth was about 1.74 cm/year faster than placebo.

If an effect like that were maintained for several years, the accumulated difference could become considerably larger — but we cannot simply multiply 1.74 × 5 and call that the final height gain. Long-term growth, puberty, bone age and whether the effect persists all matter.

Advantages
Actual Phase 3 human evidence
Oral — no injections
Demonstrated increased height velocity
Improved height Z-score
Some evidence of improved body proportionality
In the Phase 3 trial, there were no study-drug-related serious adverse events or treatment discontinuations.
N
New England Journal of Medicine
Disadvantages / concerns
It inhibits FGFR1, FGFR2 and FGFR3, rather than being exclusively FGFR3-selective.
FGFR1/2 inhibition could potentially produce unwanted effects.
Long-term effects on final adult height are still important to establish.
It is not something that should be viewed as a general-purpose height-increasing drug for people with normal growth.
Interestingly, in the Phase 3 study only 3 children (4%) had hyperphosphatemia, and these cases were mild, transient and asymptomatic. No retinal/corneal adverse events associated with FGFR1/2 inhibition were reported in the trial.
I
investor.bridgebio.com

Height-growth rating
★★★★★ — Best human evidence of these four

2. TYRA-300 / DABOGRATINIB
Current evidence: Very promising, but not yet proven in humans for height
Type: Highly selective FGFR3 inhibitor
Development for growth: Achondroplasia and other FGFR3-related skeletal conditions
Human height data: Early clinical trial — no established human height result yet

TYRA-300 is now also called dabogratinib. It is being studied in children aged 3–10 with achondroplasia and open growth plates in the Phase 2 BEACH301 study.
T
tyra.bio
+1

What happened in animals?
The preclinical results are quite striking.

In an achondroplasia mouse model, TYRA-300 increased:

Body length: about 17.9%
Tibia length: about 33.0%
Femur length: about 22.6%
Ulna length: about 23.5%
Humerus length: about 15.5%
It also partially corrected the abnormal proportions of the long bones.
P
PubMed Central (PMC)

Why is selectivity important?
TYRA-300 was designed to preferentially inhibit FGFR3, rather than strongly blocking FGFR1/2/4.

That could theoretically provide:

FGFR3 inhibition → more bone growth

while reducing:

FGFR1/2/4 inhibition → fewer unwanted effects

That's one of the main reasons TYRA-300 is interesting.

Advantages
Very strong preclinical bone-growth results
Highly selective for FGFR3
Designed specifically with skeletal dysplasias in mind
Oral drug
Human Phase 2 growth study is underway.
T
tyra.bio
Disadvantages / unknowns
The biggest issue is simple:

We don't yet know how much taller children actually become from TYRA-300.

Mouse results cannot be converted directly into human centimetres.

For example, a mouse gaining 18% body length does not mean a child would gain 18% height.

Human safety, optimal dose, growth velocity and long-term final-height effects still need to be established.

Height-growth rating
★★★★☆ — Potentially extremely interesting, but human height data are still missing

3. ERDAFITINIB
Current evidence: Not established as a height-growth treatment
Type: FGFR inhibitor, with activity against FGFR1–4
Human height data: No convincing clinical evidence that it increases height

Erdafitinib is quite different from the two drugs above because it was developed primarily as a systemic FGFR-targeting medicine rather than as a pediatric skeletal-growth treatment.

Why could it theoretically affect growth?
Because it inhibits FGFR3, it is biologically plausible that it could interfere with excessive FGFR3 signalling.

But there is a major problem:

Blocking FGFR3 isn't the only thing erdafitinib does.

It also inhibits other FGFRs, particularly FGFR1/2/4, creating more potential off-target effects.

Advantages
Potently inhibits FGFR signalling
Has human pharmacology and safety data
Provides proof that FGFR inhibition can be achieved effectively in humans
Disadvantages
The safety profile is considerably less attractive for using it as a long-term pediatric growth drug.

Reported adverse effects include:

Hyperphosphatemia
Diarrhea
Stomatitis
Nail problems
Skin problems
Eye/retinal problems
Palmar-plantar skin reactions
For example, UK prescribing information reports hyperphosphatemia in about 78.5% of treated patients and central serous retinopathy in about 28% in the relevant clinical population.


That makes erdafitinib a poor candidate to rank highly for long-term height enhancement in children, even though it does inhibit FGFR3.

Height increase?
There is no reliable number of centimetres to give.

There isn't good evidence that taking erdafitinib produces a predictable increase in height in children with achondroplasia.

Height-growth rating
★☆☆☆☆ — Theoretical FGFR3 rationale, but no established height benefit and significant safety concerns

4. LOXO-435 / VEPUGRATINIB
Current evidence: Interesting FGFR3 drug, but essentially untested for height
Type: Highly selective FGFR3 inhibitor
Human height data: No

LOXO-435 is also known as LY3866288 / vepugratinib.

It was designed to be a highly isoform-selective FGFR3 inhibitor, with the goal of avoiding some of the problems associated with broader FGFR inhibition.


Why is it interesting for growth?
The basic theory is similar to TYRA-300:

Overactive FGFR3 → excessive growth-plate braking

Therefore:

Selective FGFR3 inhibition → potentially less braking → potentially more bone growth

However, there is a major difference between biological plausibility and evidence that children actually get taller.

Where is the evidence?
LOXO-435's human clinical development is currently focused on adults with FGFR3-altered cancers, rather than children with skeletal dysplasia. The active FORAGER-1 study is a Phase 1 study in adults with advanced solid tumors.


So there is no established human height-growth result for LOXO-435.

Advantages
Highly selective for FGFR3
Designed to reduce unwanted FGFR1/2/4 inhibition
Human safety/pharmacology information is beginning to accumulate
Potentially interesting mechanism for skeletal conditions
Early human data reported mostly low-grade adverse events, although diarrhea and hyperphosphatemia were among the more common events at higher doses.


Disadvantages
No pediatric height trial
No demonstrated increase in height
No established effect on growth plates
No evidence yet for final adult height
Current clinical development is focused elsewhere
Height-growth rating
★★☆☆☆ — Interesting theoretical candidate, but currently very little evidence for height

HEAD-TO-HEAD COMPARISON
DrugFGFR selectivityHuman growth data?Evidence for increased heightCurrent confidence
InfigratinibFGFR1–3 Yes+1.74 cm/year vs placebo in Phase 3
TYRA-300FGFR3-selective Early pediatric trialStrong mouse evidence
LOXO-435FGFR3-selective No height dataTheoretical only
ErdafitinibFGFR1–4 No useful height evidenceNot established

IMPORTANT: “WHICH ONE WILL MAKE YOU TALLEST?”
Based on actual human evidence available as of August 2026:

Infigratinib
Clear winner for proven growth effect.

It is the only one of these four with a large Phase 3 placebo-controlled pediatric trial demonstrating a statistically significant increase in height velocity.


TYRA-300
Potentially the most exciting competitor.

Its animal results are impressive and its high FGFR3 selectivity is attractive, but we cannot yet say that it makes children taller by X centimetres because the human pediatric data aren't mature enough.


LOXO-435
Interesting molecule with strong FGFR3 selectivity, but no demonstrated height benefit.

Erdafitinib
Although it inhibits FGFR3, its broader FGFR activity and side-effect profile make it much less attractive as a long-term pediatric growth drug.

THE BIGGEST THING TO REMEMBER
Growth velocity ≠ final adult height.

A drug can make a child grow faster for a few years without necessarily producing the same number of extra centimetres in final adulthood.

To know which FGFR3 inhibitor ultimately gives the largest final-height increase, researchers need long-term studies following children through growth and ideally to near-final adult height.

Also, these drugs are not established ways to make otherwise healthy, normally growing people taller. The evidence we're discussing is primarily about conditions involving excessive FGFR3 signalling, particularly achondroplasia with open growth plates.


Presentation takeaway
Infigratinib currently has the strongest proof of increased height in humans. TYRA-300 has some of the most impressive preclinical bone-growth data and is being tested in children. LOXO-435 is a promising selective FGFR3 inhibitor but has no demonstrated height benefit yet. Erdafitinib inhibits FGFR3 but has no established height benefit and has a less attractive safety profile for this purpose.

 

[IAmTimoteo]

I'll read it later, but it looks good.